William B Lynch1, Christopher W Tschumi1,2, Amanda L Sharpe1,3, Sarah Y Branch2, Cang Chen4, Guo Ge4, Senlin Li4, Michael J Beckstead1,2. 1. Aging and Metabolism Research Program, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, USA. 2. Department of Cellular and Integrative Physiology, University of Texas Health, San Antonio, Texas, USA. 3. Department of Pharmaceutical Sciences, University of Oklahoma College of Pharmacy, Oklahoma City, Oklahoma, USA. 4. Department of Medicine, University of Texas Health, San Antonio, Texas, USA.
Abstract
BACKGROUND: Parkinson's disease is characterized by the progressive loss of dopamine neurons in the substantia nigra, leading to severe motor deficits. Although the disease likely begins to develop years before observable motor symptoms, the specific morphological and functional alterations involved are poorly understood. OBJECTIVES: MitoPark mice lack the gene coding for mitochondrial transcription factor A specifically in dopamine neurons, which over time produces a progressive decline of neuronal function and related behavior that phenotypically mirrors human parkinsonism. Our previous work identified a progressive decrease in cell capacitance in dopamine neurons from MitoPark mice, possibly suggesting reduced membrane surface area. We therefore sought to identify and quantify somatodendritic parameters in this model across age. METHODS: We used whole-cell patch clamp and fluorescent labeling to quantify somatodendritic morphology of single, neurobiotin-filled dopamine neurons in acutely isolated brain slices from MitoPark mice. RESULTS: We found that MitoPark mice exhibit an adult-onset, age-dependent reduction of neuritic branching and soma size in dopamine neurons. This decline proceeds similarly in MitoPark mice of both sexes, but does not begin until after the age that early decrements in ion channel physiology and behavior have previously been observed. CONCLUSIONS: A progressive and severe decline in somatodendritic morphology occurs prior to cell death, but is not responsible for the subtle decrements observable in the earliest stages of neurodegeneration. This work could help identify the ideal time window for specific treatments to halt disease progression and avert debilitating motor deficits in Parkinson's patients.
BACKGROUND:Parkinson's disease is characterized by the progressive loss of dopamine neurons in the substantia nigra, leading to severe motor deficits. Although the disease likely begins to develop years before observable motor symptoms, the specific morphological and functional alterations involved are poorly understood. OBJECTIVES:MitoPark mice lack the gene coding for mitochondrial transcription factor A specifically in dopamine neurons, which over time produces a progressive decline of neuronal function and related behavior that phenotypically mirrors humanparkinsonism. Our previous work identified a progressive decrease in cell capacitance in dopamine neurons from MitoPark mice, possibly suggesting reduced membrane surface area. We therefore sought to identify and quantify somatodendritic parameters in this model across age. METHODS: We used whole-cell patch clamp and fluorescent labeling to quantify somatodendritic morphology of single, neurobiotin-filled dopamine neurons in acutely isolated brain slices from MitoPark mice. RESULTS: We found that MitoPark mice exhibit an adult-onset, age-dependent reduction of neuritic branching and soma size in dopamine neurons. This decline proceeds similarly in MitoPark mice of both sexes, but does not begin until after the age that early decrements in ion channel physiology and behavior have previously been observed. CONCLUSIONS: A progressive and severe decline in somatodendritic morphology occurs prior to cell death, but is not responsible for the subtle decrements observable in the earliest stages of neurodegeneration. This work could help identify the ideal time window for specific treatments to halt disease progression and avert debilitating motor deficits in Parkinson'spatients.
Authors: Mats I Ekstrand; Mügen Terzioglu; Dagmar Galter; Shunwei Zhu; Christoph Hofstetter; Eva Lindqvist; Sebastian Thams; Anita Bergstrand; Fredrik Sterky Hansson; Aleksandra Trifunovic; Barry Hoffer; Staffan Cullheim; Abdul H Mohammed; Lars Olson; Nils-Göran Larsson Journal: Proc Natl Acad Sci U S A Date: 2007-01-16 Impact factor: 11.205
Authors: Cameron H Good; Alexander F Hoffman; Barry J Hoffer; Vladimir I Chefer; Toni S Shippenberg; Cristina M Bäckman; Nils-Göran Larsson; Lars Olson; Sandra Gellhaar; Dagmar Galter; Carl R Lupica Journal: FASEB J Date: 2011-01-13 Impact factor: 5.191
Authors: L Sörensen; M Ekstrand; J P Silva; E Lindqvist; B Xu; P Rustin; L Olson; N G Larsson Journal: J Neurosci Date: 2001-10-15 Impact factor: 6.167
Authors: David Ramonet; João Paulo L Daher; Brian M Lin; Klodjan Stafa; Jaekwang Kim; Rebecca Banerjee; Marie Westerlund; Olga Pletnikova; Liliane Glauser; Lichuan Yang; Ying Liu; Deborah A Swing; M Flint Beal; Juan C Troncoso; J Michael McCaffery; Nancy A Jenkins; Neal G Copeland; Dagmar Galter; Bobby Thomas; Michael K Lee; Ted M Dawson; Valina L Dawson; Darren J Moore Journal: PLoS One Date: 2011-04-06 Impact factor: 3.240
Authors: Rebecca D Howell; Sergio Dominguez-Lopez; Sarah R Ocañas; Willard M Freeman; Michael J Beckstead Journal: Neurobiol Aging Date: 2020-08-03 Impact factor: 4.673